Published by Alma
Cuba’s Biotechnology and Pharmaceutical Industry Group, BioCubaFarma, announced the creation of Innovative Immunotherapy Alliance S.A., the first Cuba-U.S. biotech joint venture, which will be based in the Mariel Special Development Zone.
The joint venture between two renowned research centers – Cuba’s Molecular Immunology Center and the Roswell Park Comprehensive Cancer Center of the United States – marks a historic step in scientific collaboration between the two countries. It will allow for advanced research and development of new cancer drugs, to improve survival rates for thousands of patients in the United States.